Allarity Therapeutics Secures Australian Patent for DRP® Platform

An update from Allarity Therapeutics ( (ALLR) ) is now available.

On June 30, 2025, Allarity Therapeutics announced that IP Australia accepted its patent application for the DRP® companion diagnostic specific to stenoparib, marking a significant step in its global strategy to protect its proprietary platform. This acceptance, covering 40 claims, is crucial for the potential international commercialization of its DRP® platform alongside stenoparib’s clinical development. The patent will be advertised in the Australian Official Journal of Patents on June 26, 2025, with a subsequent three-month opposition period. If unopposed, the patent will be granted within 20 working days. This development strengthens Allarity’s intellectual property position as it advances stenoparib through Phase 2 trials toward U.S. regulatory approval, enhancing its market positioning and offering potential implications for stakeholders.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

To see Spark’s full report on ALLR stock, click here.

More about Allarity Therapeutics

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company is advancing stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its proprietary DRP® technology to develop a companion diagnostic for patient selection. Headquartered in the U.S. with a research facility in Denmark, Allarity aims to address significant unmet medical needs in cancer treatment.

Average Trading Volume: 823,166

Technical Sentiment Signal: Sell

Current Market Cap: $15.08M

For an in-depth examination of ALLR stock, go to TipRanks’ Overview page.